神經膠質母細胞瘤 - 機會分析與預測
OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024
|出版日期||內容資訊||英文 206 Pages
|神經膠質母細胞瘤 - 機會分析與預測 OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024|
|出版日期: 2015年12月22日||內容資訊: 英文 206 Pages||
Glioblastoma multiforme (GBM) is characterized as a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB). The GBM market is currently dominated by temozolomide and Avastin which are considered as standards of care in newly diagnosed and recurrent settings, respectively. Between 2014 and 2024, the market is set to undergo substantial growth due to a number companies developing therapies in the late-stage pipeline, which is dominated by immunotherapies. On one hand, the main drivers of growth will be the launch of EGFR-targeting therapies such as Rintega and ABT-414, as well as the checkpoint inhibitor Opdivo. Furthermore, the launch of autologous cell vaccines such as ICT-107 and DCVax-L will also impact the GBM market. On the other hand, the GBM market constrainers remain modest with the increasing cost-consciousness of healthcare providers, and the launch of biosimilar bevacizumab in the 7MM (US, France, Germany, Italy, Spain, UK and Japan).
The report will enable you to -